Back to search results

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Abroad (travel likely)RecruitingPHASE2

Conditions

Rhabdomyosarcoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Stanford University, Palo Alto, California, United States

    Contact: Study coordinator (Raya Saab, MD) · rsaab@stanford.edu · 650-497-8953
    Contact: Principal Investigator (Raya Saab, MD)

  • St. Jude Children's Research Hospital, Memphis, Tennessee, United States

    Contact: Study coordinator (Alberto Pappo, MD) · referralinfo@stjude.org · 901-595-2322

  • Cook Children's Medical Center, Fort Worth, Texas, United States

    Contact: Study coordinator (Karen Albritton, MD) · karen.albritton@cookchildrens.org · 682-885-4007
    Contact: Principal Investigator (Karen Albritton)
Study leads

  • Alberto Pappo, MD

    Principal Investigator

    St. Jude Children's Research Hospital

View source on ClinicalTrials.gov(opens in a new tab)